Amgen’s low-dose Kras curveball

Amgen’s low-dose Kras curveball

Source: 
EP Vantage
snippet: 

August 16 remains a vital date in Amgen’s calendar, being the deadline by which the US FDA is to decide whether to approve the company’s Kras G12C inhibitor sotorasib. Amgen has reiterated that it is ready to launch the drug, now to be branded Lumakras, “upon approval”.